Bank of India Multi Cap Fund
The scheme seeks to generate long term capital appreciation by investing in equity and equity-related securities across various market capitalisation.
Growthvine rating: 4/5 — ranked #5 of 34 in category.
Fund basics
| Category | Equity: Multi Cap |
|---|
| NAV | ₹20.02 (as of 2026-08-21) |
|---|
| AUM | ₹1,186 Cr |
|---|
| Expense ratio | 1.86% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nitin Gosar |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 3 months |
|---|
Performance & risk
| Sharpe ratio | 0.75 |
|---|
| Standard deviation | 16.30% |
|---|
| Max drawdown | -20.69% |
|---|
| Alpha | 6.03 |
|---|
| Beta | 0.96 |
|---|
Over 5 years, captured 104.9% of NIFTY500 Multicap 50:25:25's upside and 90.8% of its downside.
Market cap allocation
| Large cap | 35.5% |
|---|
| Mid cap | 33.3% |
|---|
| Small cap | 31.1% |
|---|
Concentration
| Top 5 holdings | 19.9% |
|---|
| Top 10 holdings | 33.4% |
|---|
| Total holdings | 61 |
|---|
| Index overlap | 23.7% |
|---|
| Active share | 76.3% |
|---|
Top holdings
- HDFC Bank Ltd. — 5.8%
- TREPS — 5.7%
- Reliance Industries Ltd — 4.4%
- Dixon Technologies (India) Limited — 3.5%
- Aurobindo Pharma Ltd. — 3.2%
- FSN E-Commerce Ventures Limited — 3.0%
- Stylam Industries Limited — 2.9%
- TIPS MUSIC LIMITED — 2.8%
- Kotak Mahindra Bank Ltd. — 2.7%
- Entero Healthcare Solutions Limited — 2.6%
Top sectors
- Banking & Financial — 13.4%
- Pharma & Biotech — 11.6%
- Retail — 8.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 7.2% | Q2 | #16 of 34 |
| 2025 | 7.2% | Q1 (Top) | #2 of 31 |
| 2024 | 22.3% | Q3 | #15 of 24 |